• English
  • Polish

University of Warsaw logo

ExploRNA Therapeutics

ExploRNA Therapeutics is a spin-off company from the University of Warsaw, which is working on developing an improved mRNA with a modified 5′ cap encoding neoantigens.

The modified mRNA can be used to create experimental therapeutic anti-cancer vaccinations.

This Project will be based on the former findings of the ExploRNA team developed at the University of Warsaw, of which the Company is the sole licensee.

  • ExploRNA Therapeutics is a privately owned “spin off” company from the University of Warsaw and is led by Professor Jacek Jemielity Head of the Bio Organic Chemistry Laboratory at the Center of New Technologies CeNT at the University of Warsaw
  • ExploRNA’s mRNA therapeutics will compete in a multi-billion global marketplace that is growing at approximately 30% per year
  • ExploRNA has exclusively licensed intellectual property developed by Professor Jemielity’s group on synthetic 5 caps for mRNA that stabilize the nucleic acid enabling its application as a therapeutic
  • Professor Jemielity’s 1 st generation cap modification technology was licensed in 2011 to the German company BioNTech which has raised in excess of 580 M for the development of their mRNA based pipeline
  • ExploRNA’s next generation mRNA is expected to have significantly improved benefits in stability, translational efficiency, and cost of synthesis
  • ExploRNA’s two lead development programs will focus on tumor specific antigen vaccines and the expression of cytokines to promote cytotoxic T cells to eliminate tumor growth

ExploRNA’s founder, Professor Jemielity is one of the leading Global scientists in the mRNA field

PhD, DSc

Jacek Jemielity

ExploRNA’s founder, Professor Jemielity is one of the leading Global scientists in the mRNA field

Area of expertise

Professor Jemielity’s research is focused on synthesis of mRNA cap analogs and their biological and medicinal applications and analogs of biologically relevant nucleotides

Selected awards

Recently Nominated for European Inventor Award in the Research category (jointly with J. Kowalska and E. Darżynkiewicz)

Recipient of many top national awards such as Economic Award of the President of the Republic of Poland, and Honorary sign “For merits for inventiveness” awarded by the Prime Minister of the Republic of Poland


Co-author of more than 100 articles in leading journals (citation index >1820 and a H-index of 23) and 9 patent applications

Jacek Jemielity - ExploRNA Therapeutics

ExploRNA’s Scientific Team lead by Prof. Jemielity is a group of experienced researchers in mRNA chemistry and immuno-oncology

Joanna Kowalska - ExploRNA Therapeutics

Joanna Kowalska PhD

Assistent Profesor  at Faculty of Physics at the University of Warsaw

Area of expertise

Joanna Kowalska conducts interdisciplinary research on nucleotides and nucleic acids aimed at understanding their biological functions and finding new therapeutic solutions. She specializes, among others, in designing molecular probes to study processes related to the metabolism of nucleotides and mRNA.

Selected awards

Recipient of many national and international awards, including the national L’Oreal Award for Women in Science, nomination to the final of the “Zostańce z nami” competition organized by Polityka weekly, and nomination to the final of the European Inventor Award 2018 (together with Prof. Jacek Jemielity and Prof. Edward Darżynkiewicz). Stipends of the Foundation for Polish Science or Polish Academy of Science


Joanna Kowalska co-authored more than 70 scientific publications, a significant number of which were published in peer-reviewed international journals such as Nucleic Acids Reseach, The Journal of American Chemical Society, Organic letters, or Chemical Communications, as well as patent applications. Her work has been cited more than 1200 times to date and her Hirsch index is 21.

Jakub Gołąb - ExploRNA Therapeutics

Jakub Gołąb MD, PhD

Head of the Department of Immunology at the Medical University of Warsaw

Area of expertise

Research interests of Prof. Jakub Golab focus on experimental oncology and immunology. The major aims of these studies were associated with identification of novel molecular mechanisms of action of therapeutic approaches used in the clinical setting. These studies allowed for either improved understanding of the underlying biological effects of these therapies or led to identification of unknown interactions or even side effects of clinically approved therapeutics. Prof. Golab was appointed with Beth Israel Deaconess Medical Center Harvard Institutes of Medicine, University of Texas Southwestern Medical School and University of Calgary. Most recent research activity was associated with drug discovery and development in OncoArendi Therapeutics, a drug discovery company that was co-established by prof. Golab in 2012. Prof. Golab promoted 12 Ph.D. students. He was also a member of the first Scientific Advisory Board of the National Science Center.

Selected awards

Prof. Jakub Golab received numerous awards for his research achievements including Prime Minister Award, Jakub Karol Parnas Award from the Polish Society of Biochemistry, stipends from the Foundation for Polish Science, or Polityka, a weekly journal, among others.


Prof. Golab is a coauthor of more than 150 research articles that were cited more than 10 000 times. His Hirsh index is 37 and he published 16 articles cited >100 times (2 articles cited over 2000 times). He published in the most prestigious journals (Nature Communications, 5×Blood, 3×Leukemia, PLoS Medicine, CA A Cancer Journal for Clinicians, EMBO J, Journal of the National Cancer Institute, 3×Cancer Research, 3×Clinical Cancer Research, Cancer Immunology Research, 3xOncogene, American Journal of Pathology, 4×Journal of Medicinal Chemistry, Cell Death And Differentiation, 4×Autophagy, 2×Journal of Biological Chemistry), often as a corresponding author.

Dominika Nowis - ExploRNA Therapeutics

Dominika Nowis MD, PhD

Head of Laboratory of Experimental Medicine, Centre of New Technologies at the University of Warsaw

Area of expertise

Research interests of Prof. Dominika Nowis focus on the improvement of antitumor immune responses as well as on therapeutical targeting of protein degradation in cancer cells. She also significantly contributed to the field of the photodynamic therapy of cancer and biological activity of statins (drugs inhibiting cholesterol synthesis). For years, she has conducted research on endoplasmic reticulum stress and mechanisms of action of proteasome inhibitors. Prof. Dominika Nowis was appointed with Dana Farber Cancer Institute Harvard Medical School, Indiana University School of Medicine, University College Dublin and University of Verona. For the past 5 years she was working with prof. Vincenzo Cerundolo at MRC Weatherall Institute of Molecular Medicine at the University of Oxford. Prof. Nowis is the supervisor of 8 PhDs. She was a member of the first Young Scientists Council of the Minister of Science and Higher Education.

Selected awards

Prof. Nowis has received numerous awards for her scientific achievements. She has won, among others, a Prime Minster Award for the best habilitation thesis, the Ministry of Science and Higher Education scholarship for outstanding young scientists, START and Mentoring scholarships from the Foundation for Polish Science, L’Oreal Poland PhD scholarship for Women in Science and the “Stay with us” program of the Polityka weekly. She was repeatedly awarded with scientific prizes of JM Rector of WUM. For years she has been among the highest rated academic teachers at the Faculty of Medicine of the Medical University of Warsaw. In 2012 she took 3rd place in the first poll of “Supertalents in Medicine” of the Pulse of Medicine magazine.


Prof. Nowis is a coauthor of over 100 research articles that were cited more than 4500 times with an H index of 27. She published in the most prestigious journals (including CA: A Cancer Journal for Clinicians, 3×Nature Communications, Blood, 2×PLoS Medicine, Cancer Research, Nucleic Acid Research, 3×Clinical Cancer Research, 2×Oncogene, Journal of Immunology, Haematologica, American Journal of Pathology).

Project co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program.

Project implemented as part of the National Centre for Research and Development call: Fast Track 6/1.1.1/2019


© Copyright 2021 ExploRNA Therapeutics - All Rights Reserved